Exelixis Company Profile (NASDAQ:EXEL)

About Exelixis (NASDAQ:EXEL)

Exelixis logoExelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXEL
  • CUSIP: 30161Q10
  • Web: www.exelixis.com
Capitalization:
  • Market Cap: $8.23227 billion
  • Outstanding Shares: 293,904,000
Average Prices:
  • 50 Day Moving Avg: $27.08
  • 200 Day Moving Avg: $23.49
  • 52 Week Range: $10.04 - $29.50
P/E:
  • Trailing P/E Ratio: 123.59
  • Foreward P/E Ratio: 38.84
  • P/E Growth: 2.26
Sales & Book Value:
  • Annual Revenue: $319.67 million
  • Price / Sales: 22.50
  • Book Value: $0.51 per share
  • Price / Book: 47.98
Profitability:
  • EBIDTA: $95.32 million
  • Net Margins: 18.20%
  • Return on Equity: 80.43%
  • Return on Assets: 13.93%
Debt:
  • Current Ratio: 4.12%
  • Quick Ratio: 4.06%
Misc:
  • Average Volume: 4.17 million shs.
  • Beta: 1.97
  • Short Ratio: 4.61
 

Frequently Asked Questions for Exelixis (NASDAQ:EXEL)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings data on Wednesday, August, 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.04 by $0.02. The business earned $99.01 million during the quarter, compared to analysts' expectations of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The business's quarterly revenue was up 173.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.15) EPS. View Exelixis' Earnings History.

When will Exelixis make its next earnings announcement?

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Exelixis.

Where is Exelixis' stock going? Where will Exelixis' stock price be in 2017?

12 equities research analysts have issued twelve-month target prices for Exelixis' shares. Their predictions range from $15.00 to $33.00. On average, they expect Exelixis' share price to reach $26.20 in the next twelve months. View Analyst Ratings for Exelixis.

What are analysts saying about Exelixis stock?

Here are some recent quotes from research analysts about Exelixis stock:

  • 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
  • 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now.  Operating expenses are also projected to increase." (7/11/2017)

Who are some of Exelixis' key competitors?

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
  • Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
  • Christopher J. Senner, Chief Financial Officer, Executive Vice President
  • Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
  • Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
  • Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
  • Patrick Haley, Senior Vice President - Commercial
  • Charles M. Cohen Ph.D., Independent Director
  • Carl B. Feldbaum Esq., Independent Director
  • Alan M. Garber M.D. Ph.D., Independent Director

Who owns Exelixis stock?

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.89%), Vanguard Group Inc. (8.66%), Meditor Group Ltd (6.92%), BlackRock Inc. (5.16%), Matrix Capital Management Company LP (5.14%) and Goldman Sachs Group Inc. (2.40%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Who sold Exelixis stock? Who is selling Exelixis stock?

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Farallon Capital Management LLC, Northern Trust Corp, Teachers Advisors LLC, State Street Corp, Acadian Asset Management LLC, Voya Investment Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Who bought Exelixis stock? Who is buying Exelixis stock?

Exelixis' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Matrix Capital Management Company LP, Janus Henderson Group PLC, Meditor Group Ltd, Renaissance Technologies LLC, FMR LLC, Goldman Sachs Group Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Exelixis.

How do I buy Exelixis stock?

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of Exelixis stock can currently be purchased for approximately $24.47.


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  434
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Exelixis (NASDAQ:EXEL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $26.20 (7.05% upside)

Analysts' Ratings History for Exelixis (NASDAQ:EXEL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/22/2017Leerink SwannDowngradeOutperform -> Market PerformHighView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$32.00MediumView Rating Details
9/12/2017Needham & Company LLCReiterated RatingBuy -> Buy$28.00 -> $30.00MediumView Rating Details
9/10/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
9/10/2017Piper Jaffray CompaniesReiterated RatingBuy$29.00MediumView Rating Details
9/7/2017Stifel NicolausReiterated RatingHold$26.00LowView Rating Details
8/10/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
8/3/2017Deutsche Bank AGDowngradeBuy -> Hold$26.00 -> $29.00MediumView Rating Details
7/27/2017William BlairReiterated RatingOutperformMediumView Rating Details
7/20/2017CannReiterated RatingHoldLowView Rating Details
7/13/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$33.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
9/28/2016S&P Equity ResearchBoost Price Target$13.41 -> $15.57N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Exelixis (NASDAQ:EXEL)
Earnings by Quarter for Exelixis (NASDAQ:EXEL)
Earnings History by Quarter for Exelixis (NASDAQ EXEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.05N/AView Earnings Details
8/2/2017Q2 2017$0.04$0.06$85.27 million$99.01 millionViewListenView Earnings Details
5/1/2017Q1 2017($0.01)$0.05$65.23 million$80.90 millionViewListenView Earnings Details
2/27/2017Q416($0.01)$0.12$64.88 million$77.58 millionViewListenView Earnings Details
11/3/2016Q316($0.13)($0.04)$43.15 million$62.19 millionViewN/AView Earnings Details
8/3/2016Q216($0.27)($0.16)$16.76 million$36.25 millionViewListenView Earnings Details
5/4/2016Q116($0.25)($0.27)$9.11 million$15.40 millionViewListenView Earnings Details
2/29/2016Q415($0.22)($0.19)$8.16 million$9.94 millionViewListenView Earnings Details
11/10/2015Q315($0.20)($0.22)$9.08 million$9.85 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.22)$8.69 million$8.00 millionViewListenView Earnings Details
4/30/2015Q115($0.24)($0.18)$8.08 million$9.40 millionViewListenView Earnings Details
2/24/2015Q414($0.31)($0.30)$7.50 million$7.35 millionViewListenView Earnings Details
11/4/2014Q314($0.37)($0.32)$6.77 million$6.30 millionViewListenView Earnings Details
7/31/2014Q214($0.39)($0.38)$5.66 million$6.56 millionViewListenView Earnings Details
5/1/2014Q114($0.37)($0.39)$6.11 million$4.90 millionViewListenView Earnings Details
2/20/2014Q413($0.38)($0.38)$5.71 million$4.34 millionViewListenView Earnings Details
10/30/2013Q313($0.37)($0.36)$5.55 million$5.50 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.30)($0.34)$6.55 million$11.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.29)($0.24)$5.33 million$9.70 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.24)($0.28)$9.46 million$7.80 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.20)$9.22 million$13.30 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.25)ViewN/AView Earnings Details
5/3/2012($0.19)($0.18)ViewN/AView Earnings Details
10/27/2011$0.57$0.60ViewN/AView Earnings Details
8/4/2011($0.17)($0.16)ViewN/AView Earnings Details
5/3/2011($0.19)($0.24)ViewN/AView Earnings Details
2/22/2011($0.21)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Exelixis (NASDAQ:EXEL)
2017 EPS Consensus Estimate: $0.13
2018 EPS Consensus Estimate: $0.54
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)$0.01($0.01)
Q2 20174$0.01$0.03$0.02
Q3 20174$0.05$0.08$0.06
Q4 20174$0.04$0.07$0.06
Q1 20181$0.09$0.09$0.09
Q2 20181$0.10$0.10$0.10
Q3 20181$0.15$0.15$0.15
Q4 20181$0.20$0.20$0.20
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Exelixis (NASDAQ:EXEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Exelixis (NASDAQ:EXEL)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 79.20%
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)
Insider Trades by Quarter for Exelixis (NASDAQ:EXEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2017Stelios PapadopoulosDirectorSell10,000$25.40$254,000.00View SEC Filing  
9/19/2017Stelios PapadopoulosDirectorSell200,000$27.68$5,536,000.00View SEC Filing  
9/18/2017Stelios PapadopoulosDirectorSell72,210$27.76$2,004,549.60View SEC Filing  
9/14/2017Michael MorrisseyInsiderSell300,000$26.90$8,070,000.00View SEC Filing  
9/14/2017Patrick J. HaleyVPSell60,640$27.21$1,650,014.40View SEC Filing  
9/13/2017Lance WillseyDirectorSell100,000$26.88$2,688,000.00View SEC Filing  
9/12/2017Christopher J. SennerCFOSell100,000$26.79$2,679,000.00View SEC Filing  
5/30/2017Patrick J. HaleyInsiderSell5,000$18.46$92,300.00View SEC Filing  
5/15/2017Carl B FeldbaumDirectorSell32,988$21.58$711,881.04View SEC Filing  
5/10/2017Michael MorrisseyInsiderSell211,300$21.87$4,621,131.00View SEC Filing  
5/9/2017Michael MorrisseyCEOSell100,000$21.69$2,169,000.00View SEC Filing  
5/8/2017Michael MorrisseyCEOSell11,300$21.81$246,453.00View SEC Filing  
5/5/2017Michael MorrisseyInsiderSell259,149$22.24$5,763,473.76View SEC Filing  
5/1/2017Gisela SchwabCMOSell89,910$23.01$2,068,829.10View SEC Filing  
4/3/2017Vincent T MarchesiDirectorSell10,000$21.30$213,000.00View SEC Filing  
3/31/2017Jack L WyszomierskiDirectorSell5,150$21.57$111,085.50View SEC Filing  
3/27/2017Jeffrey HessekielEVPSell6,884$21.02$144,701.68View SEC Filing  
3/22/2017Jeffrey HessekielEVPSell23,787$20.54$488,584.98View SEC Filing  
3/20/2017Stelios PapadopoulosDirectorSell10,000$21.66$216,600.00View SEC Filing  
3/13/2017Charles CohenDirectorSell10,000$21.82$218,200.00View SEC Filing  
3/10/2017Vincent T MarchesiDirectorSell40,000$21.98$879,200.00View SEC Filing  
3/6/2017Michael MorrisseyInsiderSell200,000$22.72$4,544,000.00View SEC Filing  
3/3/2017Christopher J. SennerCFOSell11,000$22.80$250,800.00View SEC Filing  
3/2/2017George PosteDirectorSell76,250$22.53$1,717,912.50View SEC Filing  
1/3/2017Peter LambEVPSell70,000$14.65$1,025,500.00View SEC Filing  
12/16/2016Carl B. FeldbaumDirectorSell25,000$17.03$425,750.00View SEC Filing  
12/9/2016Alan M. GarberDirectorSell7,832$16.90$132,360.80View SEC Filing  
12/7/2016George A. ScangosDirectorSell204,894$17.81$3,649,162.14View SEC Filing  
12/5/2016George A. ScangosDirectorSell204,718$17.81$3,646,027.58View SEC Filing  
12/1/2016Gisela SchwabInsiderSell22,000$16.73$368,060.00View SEC Filing  
12/1/2016Peter LambEVPSell70,000$16.66$1,166,200.00View SEC Filing  
8/4/2016Gisela SchwabInsiderSell42,338$11.00$465,718.00View SEC Filing  
5/11/2016Lance WillseyDirectorBuy60,000$4.97$298,200.00View SEC Filing  
5/9/2016Lance WillseyDirectorBuy40,000$4.97$198,800.00View SEC Filing  
12/11/2015Lance WillseyDirectorBuy100,000$4.89$489,000.00View SEC Filing  
10/16/2015Peter LambEVPSell51,549$5.80$298,984.20View SEC Filing  
10/13/2015Peter LambEVPSell600$5.80$3,480.00View SEC Filing  
10/12/2015Peter LambEVPSell300,276$5.84$1,753,611.84View SEC Filing  
9/17/2014Vincent T MarchesiDirectorBuy20,000$1.71$34,200.00View SEC Filing  
8/29/2013Lance WillseyDirectorBuy10,000$5.15$51,500.00View SEC Filing  
12/20/2012Vincent T MarchesiDirectorBuy4,000$4.68$18,720.00View SEC Filing  
12/19/2012Vincent T MarchesiDirectorBuy6,000$4.72$28,320.00View SEC Filing  
12/10/2012Gisela SchwabEVPBuy25,000$4.39$109,750.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Exelixis (NASDAQ:EXEL)
Latest Headlines for Exelixis (NASDAQ:EXEL)
Source:
DateHeadline
seekingalpha.com logoExelixis resumes down move, shares off 13%
seekingalpha.com - September 23 at 6:10 PM
benzinga.com logoThe Street Has Finally Recognized The Exelixis Clinical Program Potential
www.benzinga.com - September 23 at 9:48 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Director Sells $254,000.00 in Stock
www.americanbankingnews.com - September 22 at 7:52 PM
fool.com logoWhy Exelixis, Inc. Slumped Today
www.fool.com - September 22 at 3:37 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Downgraded to Market Perform at Leerink Swann
www.americanbankingnews.com - September 22 at 8:47 AM
americanbankingnews.com logoStelios Papadopoulos Sells 200,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 20 at 7:36 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Director Sells $2,004,549.60 in Stock
www.americanbankingnews.com - September 20 at 7:34 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - September 20 at 9:24 AM
businesswire.com logoExelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25 - Business Wire (press release)
www.businesswire.com - September 20 at 4:38 AM
finance.yahoo.com logoExelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25
finance.yahoo.com - September 19 at 6:32 PM
thestreet.com logoU.S. FDA Grants Fast Track Designation To Pluristem's PLX-PAD For The Treatment Of Critical Limb Ischemia (CLI)
www.thestreet.com - September 18 at 6:19 PM
nasdaq.com logoExelixis Inc (EXEL) President and CEO Michael Morrissey Sold $8.1 million of Shares
www.nasdaq.com - September 16 at 12:03 AM
americanbankingnews.com logoPatrick J. Haley Sells 60,640 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 15 at 7:24 PM
fool.com logoWho Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
www.fool.com - September 15 at 6:43 AM
finance.yahoo.com logoExelixis, Inc. – Value Analysis (NASDAQ:EXEL) : September 15, 2017
finance.yahoo.com - September 15 at 12:15 AM
americanbankingnews.com logoMichael Morrissey Sells 300,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 14 at 10:35 PM
americanbankingnews.com logoInsider Selling: Exelixis, Inc. (EXEL) Director Sells 100,000 Shares of Stock
www.americanbankingnews.com - September 14 at 10:34 PM
americanbankingnews.com logoChristopher J. Senner Sells 100,000 Shares of Exelixis, Inc. (EXEL) Stock
www.americanbankingnews.com - September 14 at 10:32 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Earns Outperform Rating from Analysts at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 5:26 PM
fool.com logoExelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale
www.fool.com - September 14 at 3:45 PM
finance.yahoo.com logoExelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : September 13, 2017
finance.yahoo.com - September 13 at 7:52 PM
americanbankingnews.com logoFY2018 EPS Estimates for Exelixis, Inc. (EXEL) Increased by Analyst
www.americanbankingnews.com - September 13 at 1:22 PM
americanbankingnews.com logoWilliam Blair Analysts Raise Earnings Estimates for Exelixis, Inc. (EXEL)
www.americanbankingnews.com - September 12 at 4:50 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Price Target Raised to $30.00
www.americanbankingnews.com - September 12 at 9:32 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Earns Hold Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 11 at 3:12 PM
americanbankingnews.com logoExelixis' (EXEL) Buy Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - September 11 at 3:12 PM
fool.com logoWhy Exelixis, Inc. Could Be a Gold Mine for Growth Investors - Motley Fool
www.fool.com - September 10 at 10:50 PM
americanbankingnews.com logoAnalyzing Exelixis (EXEL) and Cascadian Therapeutics (CASC)
www.americanbankingnews.com - September 10 at 8:24 PM
finance.yahoo.com logoWhy Exelixis, Inc. Could Be a Gold Mine for Growth Investors
finance.yahoo.com - September 10 at 5:47 PM
fool.com logo2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August - Motley Fool
www.fool.com - September 8 at 6:57 PM
fool.com logo2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August
www.fool.com - September 8 at 11:44 AM
americanbankingnews.com logoExelixis, Inc. (EXEL) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - September 7 at 10:44 PM
businesswire.com logoExelixis Debuts New Mission-Driven Corporate Branding That ... - Business Wire (press release)
www.businesswire.com - September 7 at 6:35 PM
finance.yahoo.com logoExelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy
finance.yahoo.com - September 7 at 6:35 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Exelixis, Inc. (EXEL) Will Announce Quarterly Sales of $103.83 Million
www.americanbankingnews.com - September 7 at 6:32 AM
businesswire.com logoExelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress - Business Wire (press release)
www.businesswire.com - September 6 at 11:30 PM
finance.yahoo.com logoExelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress
finance.yahoo.com - September 6 at 6:29 PM
americanbankingnews.com logo Brokerages Expect Exelixis, Inc. (EXEL) to Post $0.07 Earnings Per Share
www.americanbankingnews.com - September 5 at 10:26 AM
nasdaq.com logoCan Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions? - Nasdaq
www.nasdaq.com - September 2 at 5:42 PM
finance.yahoo.com logoCan Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - September 1 at 6:54 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation
finance.yahoo.com - August 31 at 6:23 PM
businesswire.com logoExelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 - Business Wire (press release)
www.businesswire.com - August 30 at 5:04 AM
finance.yahoo.com logoAnalyst Recommendations for Regeneron Pharmaceuticals in August
finance.yahoo.com - August 29 at 7:01 PM
finance.yahoo.com logoExelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13
finance.yahoo.com - August 29 at 7:01 PM
bizjournals.com logoStock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma, and Intra Cellular Therapies
www.bizjournals.com - August 28 at 6:17 PM
prnewswire.com logoStock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma ...
www.prnewswire.com - August 28 at 6:17 PM
fool.com logoCan Buying Exelixis Stock Still Make You Rich?
www.fool.com - August 27 at 4:06 PM
americanbankingnews.com logoExelixis, Inc. (EXEL) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 26 at 8:44 AM
americanbankingnews.com logoBidaskClub Upgrades Exelixis, Inc. (EXEL) to Strong-Buy
www.americanbankingnews.com - August 25 at 9:44 PM
globenewswire.com logoAtara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
globenewswire.com - August 23 at 12:05 AM

Social

Chart

Exelixis (EXEL) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff